News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
890,159 Results
Type
Article (88547)
Company Profile (553)
Press Release (801058)
Multimedia
Podcasts (234)
Webinars (34)
Section
Business (267230)
Career Advice (4173)
Deals (40075)
Drug Delivery (171)
Drug Development (91406)
Employer Resources (206)
FDA (18393)
Job Trends (17524)
News (398453)
Policy (40016)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (2)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (7)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (3)
2027 Biotech Beach Standard (4)
2027 Genetown Elite (5)
2027 Genetown Standard (8)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (8)
Academia (3083)
Academic (2)
Accelerated approval (58)
ADA (48)
Adcomms (29)
Allergies (217)
Alliances (56993)
ALS (243)
Alzheimer's disease (2062)
Antibody-drug conjugate (ADC) (644)
Approvals (19081)
Artificial intelligence (992)
ASCO (331)
Autoimmune disease (420)
Automation (72)
Bankruptcy (412)
Belgium (4)
Best Places to Work (12631)
BIO (81)
Biologics (13)
BIOSECURE Act (23)
Biosimilars (276)
BioSpace Insights (196)
Biotechnology (336)
Bispecific (1)
Bladder cancer (224)
Brain cancer (90)
Breast cancer (889)
Cancer (7097)
Cardiovascular disease (583)
Career advice (3619)
Career pathing (60)
CAR-T (407)
CDC (77)
CDMO (158)
Celiac Disease (4)
Cell therapy (1126)
Cervical cancer (61)
Clinical research (79681)
Collaboration (2631)
Commercialization (11)
Company closure (10)
Compensation (1768)
Complete response letters (103)
COVID-19 (3048)
CRISPR (136)
C-suite (1542)
Cystic fibrosis (174)
Data (9641)
Decentralized trials (3)
Denatured (85)
Depression (199)
Dermatology (129)
Diabetes (725)
Diagnostics (7786)
Digital health (79)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (482)
Drug pricing (244)
Drug shortages (34)
Duchenne muscular dystrophy (331)
Earnings (103681)
Editorial (72)
Employer branding (25)
Employer resources (177)
Events (139994)
Executive appointments (1310)
FDA (23083)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (1)
Friedreich's ataxia (24)
Frontotemporal dementia (36)
Funding (2164)
Gene editing (291)
Generative AI (93)
Gene therapy (860)
GLP-1 (1265)
Government (5571)
Grass and pollen (8)
Guidances (435)
Healthcare (21371)
Hematology (191)
HIV (110)
Huntington's disease (71)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (129)
Immunology and inflammation (347)
Immuno-oncology (127)
Indications (245)
Infectious disease (3465)
Inflammatory bowel disease (245)
Inflation Reduction Act (17)
Influenza (157)
Intellectual property (359)
Interviews (826)
IPO (18042)
IRA (60)
Job creations (5211)
Job search strategy (2879)
JPM (68)
Kidney cancer (25)
Labor market (133)
Layoffs (710)
Leadership (59)
Legal (10169)
Licensing (27)
Liver cancer (115)
Longevity (42)
Lung cancer (950)
Lymphoma (508)
Machine learning (74)
Management (68)
Manufacturing (1412)
Marketing (14)
MASH (236)
Medical affairs (3)
Medical device (15403)
Medtech (15664)
Mergers & acquisitions (23492)
Metabolic disorders (1853)
mRNA (297)
Multiple sclerosis (222)
Multispecific (1)
NASH (24)
Netherlands (3)
Neurodegenerative disease (538)
Neuropsychiatric disorders (124)
Neuroscience (3941)
Neurotech (2)
NextGen: Class of 2026 (7713)
Non-profit (5161)
Now hiring (91)
Obesity (842)
Opinion (372)
Ovarian cancer (262)
Pain (306)
Pancreatic cancer (392)
Parkinson's disease (447)
Partnered (38)
Patents (752)
Patient advocacy (1)
Patient recruitment (943)
Patient selection (1)
Peanut (73)
People (68640)
Peptides (6)
Pharmaceutical (81)
Pharmacy benefit managers (40)
Phase 1 (24646)
Phase 2 (34592)
Phase 3 (26024)
Pipeline (12104)
Policy (389)
Postmarket research (3552)
Preclinical (11048)
Press Release (72)
Prostate cancer (375)
Psychedelics (74)
Radiopharmaceuticals (403)
Rare diseases (1347)
Real estate (7473)
Recruiting (81)
Regulatory (31021)
Reports (90)
Research institute (2801)
Resumes & cover letters (656)
Rett syndrome (52)
RNA editing (33)
RSV (98)
Schizophrenia (199)
Series A (368)
Series B (269)
Service/supplier (16)
Sickle cell disease (136)
Special edition (32)
Spinal muscular atrophy (191)
Sponsored (58)
Startups (4386)
State (2)
Stomach cancer (16)
Supply chain (149)
Tariffs (105)
The Weekly (146)
Vaccines (1360)
Venture capital (149)
Weight loss (550)
Women's health (161)
Worklife (26)
Date
Today (49)
Last 7 days (677)
Last 30 days (2301)
Last 365 days (33048)
2026 (23353)
2025 (32881)
2024 (37630)
2023 (42564)
2022 (53927)
2021 (58720)
2020 (57663)
2019 (51334)
2018 (39119)
2017 (37188)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1301)
Alabama (111)
Alaska (7)
Arizona (454)
Arkansas (16)
Asia (52766)
Australia (9288)
California (15816)
Canada (4417)
China (1818)
Colorado (674)
Connecticut (706)
Delaware (489)
Europe (121710)
Florida (2407)
Georgia (520)
Hawaii (5)
Idaho (70)
Illinois (1374)
India (132)
Indiana (713)
Iowa (30)
Japan (694)
Kansas (151)
Kentucky (64)
Louisiana (68)
Maine (95)
Maryland (1890)
Massachusetts (11511)
Michigan (454)
Minnesota (873)
Mississippi (7)
Missouri (180)
Montana (37)
Nebraska (31)
Nevada (173)
New Hampshire (92)
New Jersey (4159)
New Mexico (38)
New York (4142)
North Carolina (2089)
North Dakota (11)
Northern California (7990)
Ohio (505)
Oklahoma (31)
Oregon (49)
Pennsylvania (3046)
Puerto Rico (33)
Rhode Island (56)
South America (1672)
South Carolina (96)
South Dakota (2)
Southern California (6272)
Tennessee (264)
Texas (2597)
United States (56304)
Utah (474)
Vermont (2)
Virginia (398)
Washington D.C. (88)
Washington State (1282)
West Virginia (4)
Wisconsin (178)
Wyoming (4)
890,159 Results for "f hoffmann la roche ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
La Roche-Posay Announces 2025 Young Investigator Grant Winners and Opens Applications for 2026 Program
August 17, 2026
·
3 min read
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.
July 13, 2026
·
4 min read
·
Heather McKenzie
Multiple sclerosis
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche’s own BTK inhibitor fenebrutinib.
September 2, 2026
·
2 min read
·
Tristan Manalac
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
Roche’s decision to discontinue the Ionis-partnered trials came soon after the biotech sustained a late-stage failure in ATTR-CM.
July 10, 2026
·
2 min read
·
Tristan Manalac
Cancer
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases including lymphoma and autoimmune conditions.
September 1, 2026
·
2 min read
·
Annalee Armstrong
Rare diseases
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
July 28, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Roche pours $750M into Oregon manufacturing plant as obesity push expands
After committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche’s Genentech is putting down more cash to expand a device fill-finish site in Oregon.
August 20, 2026
·
1 min read
·
Gabrielle Masson
Obesity
Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug
Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.
August 24, 2026
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms
Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.
June 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States
August 20, 2026
·
3 min read
1 of 89,016
Next
